6 November 2019 - States offer relief from price-inflating prescription drug middlemen.

Few policy issues have consumed Washington more over the past year than the debate over what to do about prescription drug prices.

Many around the country have pointed fingers at pharmaceutical companies and insurers for these price increases, but people are beginning to realise that the true problem lies with the middlemen in between — pharmacy benefit managers.

Read Washington Times article